Tag: Schizophrenia treatment

The dopamine hypothesis of schizophrenia, first proposed in the 1960s, suggests that certain symptoms are linked to disturbed dopamine signaling in the brain. For individuals with this condition, understanding what dopamine drugs are used for schizophrenia is crucial, as medication is a cornerstone of managing psychotic symptoms.

Developed in 1950, chlorpromazine was the first antipsychotic medication, revolutionizing psychiatric care. But in an era of newer drugs, **do people still use chlorpromazine?** This pioneering medication remains in use for specific conditions, though less commonly than in the past.

The discontinuation of fluphenazine decanoate (Modecate) around 2018 was primarily due to manufacturing difficulties and unpredictable supplies of its active pharmaceutical ingredient [1.2.2, 1.4.3]. This article delves into why was fluphenazine discontinued and the impact on patients.

An estimated 4.4% of U.S. adults experience bipolar disorder at some point in their lives, and schizophrenia affects between 0.25% and 0.64% of the adult population. For these individuals, understanding treatment is key. So, how does Caplyta make you feel when used for these conditions?

In clinical trials for Invega Sustenna, approximately 3% of patients experienced diarrhea, compared to 2% on a placebo [1.2.3]. This article examines the question: **Does paliperidone cause diarrhea**, its mechanisms, and how to manage this side effect?

Medication non-adherence rates in schizophrenia are estimated to be around 50%, making long-acting injectables a crucial treatment option [1.6.3]. While both medications contain the same active drug, the answer to 'Is Perseris the same as Risperdal Consta?' lies in their significant differences in administration and formulation.

Effective July 9, 2024, pharmaceutical company Indivior announced it would discontinue all sales and marketing activities for its schizophrenia drug, Perseris. This strategic move was not prompted by any safety or efficacy issues with the product but was a business decision based on financial viability, which answers the question: **Why is Perseris being discontinued**?. The market withdrawal was driven by increased payor management impacts and a competitive market landscape influenced by the Inflation Reduction Act.

In the United States, adherence rates for oral antipsychotics can be as low as 40% to 60% [1.7.5]. To address this, long-acting injectables like Perseris offer a different approach, but a key question for healthcare providers is: **Is Perseris IM or subq?**

According to prescription data from early 2025, quetiapine fumarate is the most frequently prescribed antipsychotic medication in the U.S., often used for schizophrenia and bipolar disorder. However, there is no single best or most common drug used for schizophrenia for every patient, as treatment is highly individualized and depends on a person's unique symptoms and response to medication.

According to the National Institutes of Health, while most antipsychotics effectively treat positive symptoms like hallucinations, atypical antipsychotics have shown greater efficacy in addressing the debilitating negative symptoms of schizophrenia. This difference is rooted in their unique pharmacological mechanisms and complex interactions with various neurotransmitter systems beyond simple dopamine blockade.